Switch theme
Sign up to access all valuation multiples
Nanexa AB is a pharmaceutical company developing injectable drug products based on the proprietary drug delivery system PharmaShell - the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. The company develops its products and also has collaboration agreements with several pharma companies, among others AstraZeneca. Geographically, the company derives maximum revenue from Nordic countries.
2007
17
Last FY Revenue $2.5M
Last FY EBITDA -$1.4M
$30.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Nanexa achieved revenue of $2.5M and an EBITDA of -$1.4M.
Nanexa expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Nanexa valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $2.5M | XXX | XXX | XXX |
| Gross Profit | XXX | $4.8M | XXX | XXX | XXX |
| Gross Margin | XXX | 192% | XXX | XXX | XXX |
| EBITDA | XXX | -$1.4M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -56% | XXX | XXX | XXX |
| EBIT | XXX | -$2.7M | XXX | XXX | XXX |
| EBIT Margin | XXX | -108% | XXX | XXX | XXX |
| Net Profit | XXX | -$2.6M | XXX | XXX | XXX |
| Net Margin | XXX | -102% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Nanexa's stock price is SEK 2 (or $0).
Nanexa has current market cap of SEK 319M (or $32.9M), and EV of SEK 292M (or $30.1M).
See Nanexa trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $30.1M | $32.9M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Nanexa has market cap of $32.9M and EV of $30.1M.
Nanexa's trades at 12.0x EV/Revenue multiple, and -21.3x EV/EBITDA.
Equity research analysts estimate Nanexa's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nanexa's P/E ratio is not available.
See valuation multiples for Nanexa and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $32.9M | XXX | $32.9M | XXX | XXX | XXX |
| EV (current) | $30.1M | XXX | $30.1M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 12.0x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -21.3x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -11.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -12.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -5.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNanexa's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.4M for the same period.
Nanexa's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nanexa's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Nanexa and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -56% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 68% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 300% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nanexa acquired XXX companies to date.
Last acquisition by Nanexa was XXXXXXXX, XXXXX XXXXX XXXXXX . Nanexa acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Nanexa founded? | Nanexa was founded in 2007. |
| Where is Nanexa headquartered? | Nanexa is headquartered in Sweden. |
| How many employees does Nanexa have? | As of today, Nanexa has 17 employees. |
| Is Nanexa publicy listed? | Yes, Nanexa is a public company listed on STO. |
| What is the stock symbol of Nanexa? | Nanexa trades under NANEXA ticker. |
| When did Nanexa go public? | Nanexa went public in 2015. |
| Who are competitors of Nanexa? | Similar companies to Nanexa include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Nanexa? | Nanexa's current market cap is $32.9M |
| Is Nanexa profitable? | Yes, Nanexa is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
